The safety profile of a protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe for interstitial lung disease

Respir Med. 2022 Aug-Sep:200:106913. doi: 10.1016/j.rmed.2022.106913. Epub 2022 Jun 6.

Abstract

Introduction: Transbronchial lung cryobiopsy (TBLC) has emerged as a promising alternative to surgical lung biopsy for the diagnosis of interstitial lung disease. However, uncertainty remains regarding its overall complications due to a lack of procedural standardization including the size of cryoprobe utilized.

Methods: This is a prospective cohort study of a protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe. 201 consecutive subjects were enrolled at a single academic center.

Results: The average biopsy size was 106.2 ± 39.3 mm2. Complications included a total pneumothorax rate of 4.9% with 3.5% undergoing chest tube placement. Severe bleeding defined by the Nashville Working Group occurred in 0.5% of cases. There were no deaths at 30-days.

Discussion: A protocolized transbronchial cryobiopsy program utilizing a 2.4 mm cryoprobe in can achieve a high diagnostic yield with a favorable safety profile.

MeSH terms

  • Biopsy / adverse effects
  • Bronchoscopy* / adverse effects
  • Humans
  • Lung / pathology
  • Lung Diseases, Interstitial* / diagnosis
  • Lung Diseases, Interstitial* / pathology
  • Prospective Studies